Target ALS
  • NEWS
  • DONATE
  • ABOUT US
    • CHALLENGE
    • OUR APPROACH
    • OUR IMPACT
    • ABOUT ALS
  • RESOURCES FOR SCIENTISTS
    • HUMAN POSTMORTEM TISSUE CORE
    • GENOMIC DATASETS
    • STEM CELL CORE
    • ANIMAL MODELS
    • IN VIVO TARGET VALIDATION CORE
    • VIRAL VECTOR CORE
    • ANTIBODY CORE
    • LONGITUDINAL BIOFLUIDS CORE
  • RESEARCH
    • FUNDED CONSORTIA
    • ANNUAL MEETING
    • PUBLICATIONS
  • FUNDING OPPORTUNITIES
  • COMMUNITY
    • FOUNDER
    • LEADERSHIP
    • SCIENTISTS
    • SPRINGBOARD FELLOWS
    • PARTNERS
  • TAKE ACTION
    • CONTACT US
    • EMAIL SIGN UP
    • DONATE NOW
    • WAYS TO GIVE
Select Page
n-Lorem Foundation and Columbia University Establish Silence ALS Initiative

n-Lorem Foundation and Columbia University Establish Silence ALS Initiative

by Melissa Rentfrow | May 3, 2022 | News

Silence ALS initiative will offer an integrated solution to identify, support and potentially treat nano-rare ALS patients. n-Lorem foundation and Columbia University receive a founding donation from Target ALS of $400,000 to formalize the Silence ALS initiative and...
Alzheimer’s Drug Discovery Foundation (ADDF) and Target ALS Announce Partnership to Accelerate Biomarker Discovery and Development

Alzheimer’s Drug Discovery Foundation (ADDF) and Target ALS Announce Partnership to Accelerate Biomarker Discovery and Development

by Steve Schonberg | Dec 21, 2021 | News

Collaboration, with Support from the ADDF’s Diagnostics Accelerator, Will Create Funding Opportunities to Advance Potential Biomarkers in Related Neurodegenerative Diseases. The Alzheimer’s Drug Discovery Foundation (ADDF) and Target ALS announced today a new...
Thanks to Your Support: $35 Million Raised in 2019

Thanks to Your Support: $35 Million Raised in 2019

by Steve Schonberg | Jan 2, 2020 | Fundraising

Case Study: Collaboration Accelerates Potential ALS Treatment

Case Study: Collaboration Accelerates Potential ALS Treatment

by Target ALS | Oct 19, 2018 | Collaboration

One of the early Target ALS-supported consortia studying C9orf72 ALS put forward the idea that it may be possible to treat ALS by targeting C9orf72 peptides directly. To move this idea forward, Target ALS connected Neurimmune, a biotechnology company with a group of...
Case Study: Consortium Explores KPT-350 as a Potential Treatment for ALS

Case Study: Consortium Explores KPT-350 as a Potential Treatment for ALS

by Target ALS | Oct 19, 2018 | Hear From the Scientists

The ALS drug KPT-350 was one of the first of a dozen therapeutic options to emerge from the Target ALS Innovation Ecosystem and is now poised for clinical trial thanks to the power of collaboration. Shortly after its launch, Target ALS forged and funded one of the...
« Older Entries

  • Challenge
  • Contact
  • Our Approach
  • Resources For Scientists
  • Donate
  • Call For Proposals
  • Funded Consortia
  • Annual Meeting
  • Privacy Policy
  • Credits

FOLLOW US

  • Instagram
  • Facebook
  • Instagram
  • Twitter

Support Target ALS

When you shop at smile.amazon.com,
Amazon donates.
Go to smile.amazon.com

The Target ALS (TALS) website is intended for informational purposes only. Opinions expressed may not be that of TALS or its employees. For more information about our digital policies, click here.

AmazonSmile and the AmazonSmile logo are trademarks of Amazon.com, Inc. or its affiliates

© 2022 Target ALS Foundation, Inc.
Target ALS Foundation
P.O. Box 1598
New York, NY 10101
(332) 333-4140
Steck Insights WordPress Consulting